See Bull Run's current pages for Sun Pharmaceutical Industries and Torrent Pharmaceuticals. For a different pharmaceutical business model, see Bull Run's Sun Pharma vs Divi's Laboratories comparison.

Sun generated approximately 3.1 times Torrent's quarterly revenue.

It also generated approximately 2.7 times Torrent's EBITDA and more than five times Torrent's reported PAT.

Q1 FY27 financial scorecard

Torrent's 55% growth number needs to be decomposed

This distinction is essential.

A 55% reported growth rate sounds like an extraordinary organic acceleration.

It is not.

Torrent's operating business still performed very strongly, but acquisition accounting enlarged the consolidated revenue base.

The correct way to analyse the quarter is to separate:

• Torrent base business;
• JB Pharma business;
• integration synergies;
• acquisition-related financing and depreciation.

Torrent's base business itself was excellent

Base-business revenue reached approximately ₹3,720 crore and grew 17%.

Operating EBITDA reached approximately ₹1,240 crore, up 20%.

Base-business EBITDA margin was 33.3%.

This is an impressive margin for a pharmaceutical company with large sales and marketing infrastructure.

India is Torrent's central economic engine

Torrent's growth came from a combination of volume, price increases and new products.

The company is especially strong in chronic therapies.

It now ranks first in India's cardiac market according to its Q1 disclosures.

Chronic therapies are strategically attractive because patients often remain on medication for long periods.

This can create recurring prescriptions and strong physician relationships.

Sun remains far larger in India

Sun's India formulations generated approximately ₹5,475 crore during Q1.

That is about 2.5 times Torrent's base India revenue.

Sun grew 16% and increased domestic market share to approximately 8.5%.

The company maintains prescription leadership across numerous doctor specialties.

Scale matters because a larger field force and deeper therapy portfolio can support more new-product launches.

But Torrent's India growth was faster

Torrent's 19% base India growth exceeded Sun's 16%.

The difference is only three percentage points, but Torrent starts from a much smaller base.

If Torrent can sustain high-teens domestic growth for several years, India can become an even larger part of consolidated profit.

JB Pharma substantially strengthens Torrent's India platform

JB Pharma generated ₹1,201 crore total Q1 revenue.

Its India prescription business, excluding trade generics and contrast media, generated approximately ₹657 crore and grew 13%.

The JB portfolio adds brands, therapies, medical-representative capacity and manufacturing assets.

The strategic logic is to increase revenue per field representative while eliminating duplicated corporate costs.

The most impressive JB number is the margin

JB Pharma generated approximately ₹424 crore operating EBITDA.

That represents a 35.3% margin, up substantially from the prior-year period.

Cost synergies were implemented faster than initially expected.

That gives Torrent an unusually high-margin acquired platform.

But investors should distinguish genuine recurring synergies from one-time cost resets.

Torrent's consolidated margin is now above Sun's

Torrent's 33.8% operating EBITDA margin compares with Sun's 28.9%.

The five-percentage-point gap is meaningful.

Torrent benefits from a high branded-formulation mix, particularly India and Brazil.

Sun carries more R&D spending, global generic exposure and a larger innovative-medicines development pipeline.

Margin alone still does not make Torrent the better business

Torrent's Q1 PAT was only ₹566 crore despite ₹1,664 crore operating EBITDA.

Sun generated approximately ₹2,895 crore reported PAT on ₹4,418 crore EBITDA.

Torrent has higher finance and depreciation costs following acquisition-led expansion.

That means the margin advantage does not fully translate into shareholder earnings today.

Sun is building a different type of pharmaceutical franchise

Sun is increasingly trying to own differentiated medicines rather than only market branded generics.

The strategy requires higher R&D spending and greater clinical risk.

But a successful innovative product can create longer-duration pricing power than a conventional generic.

Torrent remains more branded-generics driven

Torrent has excellent brands and physician relationships but less direct innovative-specialty exposure than Sun.

Its economic edge comes from:

• chronic-therapy leadership;
• high field-force productivity;
• brand acquisition;
• product launches;
• price growth;
• operating leverage;
• cost synergies.

This model can generate extremely high margins without carrying the same level of novel-drug clinical risk.

Which model is more predictable?

Torrent's established domestic branded portfolio can be more predictable at the individual-product level.

Sun's innovative pipeline introduces binary regulatory and clinical milestones.

However, Sun's far greater geographic and therapy diversification reduces company-level dependence on any one commercial outcome.

Predictability therefore operates differently at the product and corporate levels.

The US businesses are moving in opposite directions

Sun's US formulations fell 9.7% to US$427 million.

Innovative Medicines grew, but generic declines remained a drag.

Torrent's US revenue rose 36% to ₹418 crore, with constant-currency growth around 23%.

Torrent said the quarter benefited from new launches and certain one-time opportunities.

The scale remains far smaller than Sun's US business.

Torrent wants the US business to become profitable

Torrent's US generics operation has historically been a weaker contributor than its India franchise.

Management has indicated a goal of reaching profitability during FY27.

If achieved, the US business can become a positive earnings lever rather than a drag.

But Q1 included certain one-time revenue opportunities, so the 36% reported growth should not automatically be extrapolated.

Brazil is another major Torrent strength

Brazil revenue reached approximately ₹277 crore and grew 27% in rupee terms.

Constant-currency growth was much lower at roughly 3% because of a one-time channel inventory reduction.

Underlying prescription-market data remained stronger than the reported primary-sales number.

Torrent has built one of the strongest Brazilian franchises among Indian pharmaceutical companies.

Sun has much broader Emerging Market exposure

Sun's Emerging Markets formulations generated US$311 million in Q1 FY27.

Revenue grew 4.2%.

Its markets include countries across Latin America, Eastern Europe, Africa and Asia.

This geographic breadth lowers dependence on one country such as Brazil.

Germany remains Torrent's weak spot

Torrent's Germany revenue was approximately ₹318 crore and grew only 3% in rupees.

Constant-currency revenue declined around 9%.

Supply disruption at a third-party supplier and lower tender offtake hurt the quarter.

This business has lower structural pricing power than Torrent's branded India franchise.

Semaglutide shows how both companies are attacking the same new market

Both companies have entered the rapidly expanding GLP-1 and semaglutide opportunity.

Sun launched semaglutide products in India and received approvals in additional international markets during 2026.

Torrent disclosed approximately 36% combined Q1 market share for its generic oral and injectable semaglutide portfolio in India.

The approaches illustrate their strategic differences.

Sun is using global peptide-development and commercial capability.

Torrent is using domestic branded execution and its physician network.

Sun spends more heavily on future innovation

Sun invested approximately ₹826 crore in R&D during Q1, equal to 5.4% of sales.

Torrent spent approximately ₹172 crore, around 4% of revenue.

Sun's absolute R&D spend was therefore almost five times Torrent's.

Part of Sun's spending supports innovative clinical programmes with much longer development horizons.

The acquisition strategies now create very different balance-sheet profiles

This is one of the most important differences in the current comparison.

Sun has historically carried a very conservative balance sheet.

Torrent has deliberately used leverage to accelerate acquisition-led growth.

Leverage can amplify Torrent's ROE

Bull Run's current ROE for Torrent is approximately 27.1%, compared with Sun around 14.7%.

At first glance, Torrent appears much more efficient with equity capital.

But Torrent also carries materially more financial leverage.

Higher debt reduces the equity base and can mathematically raise ROE when acquisitions perform well.

ROCE therefore provides another useful perspective.

ROCE currently favours Sun

Sun's ROCE is materially higher despite lower ROE.

That reflects its low leverage.

Torrent's challenge is to use acquisition debt productively enough that future operating earnings grow faster than interest and depreciation costs.

The JB acquisition can still create substantial value

Torrent does not need leverage to remain permanently high.

If JB synergies increase EBITDA while cash generation reduces debt, net debt to EBITDA can fall quickly.

That can create a powerful earnings and equity-value combination:

• higher operating profit;
• lower finance cost;
• lower leverage;
• potential valuation support.

The risk is that integration benefits disappoint or growth slows before deleveraging occurs.

Sun's proposed Organon transaction creates its own future leverage question

Sun's balance-sheet advantage should not simply be projected forever.

The proposed Organon acquisition is much larger than Sun's normal product or licensing transactions.

If completed, the financing structure and integration plan can materially change leverage, revenue mix and earnings.

The Q1 comparison therefore captures Sun before that transaction closes.

Valuation is where Sun has the largest advantage

Torrent trades at roughly twice Sun's trailing P/E.

Its price-to-book multiple is more than three times Sun's.

This is a demanding valuation for a company whose current ROCE is lower and whose balance sheet is more leveraged.

The premium reflects:

• high branded margins;
• fast India growth;
• JB synergies;
• strong chronic-therapy positioning;
• high ROE;
• potential deleveraging.

Torrent's market cap is only 36% of Sun's—but PAT is only 20%

Sun's market capitalisation is approximately ₹4.69 lakh crore.

Torrent's is approximately ₹1.70 lakh crore.

Torrent is therefore valued at roughly 36% of Sun's market capitalisation.

But its Q1 PAT was only about 20% of Sun's.

This demonstrates how aggressively the market values Torrent's future growth and synergies.

Sun's lower multiple provides more room for imperfect execution

Sun does not need to maintain Torrent-like high-teens India growth everywhere to justify its valuation.

Its earnings base is broader and the starting multiple is lower.

That does not remove risk.

But it reduces the amount of future growth already embedded in the price.

Torrent's one-year rerating raises the hurdle further

Bull Run's September snapshot shows Torrent up approximately 38.5% over one year.

Sun is up around 23.4%.

Torrent's operating execution has earned a substantial rerating.

From here, future returns are more dependent on earnings delivery and deleveraging than another large expansion in P/E.

What must Sun Pharma prove?

• India formulations should sustain double-digit growth.
• Innovative Medicines need continued global expansion.
• US generic weakness must stabilise.
• R&D investment needs successful regulatory milestones.
• Semaglutide and peptide products should generate durable sales.
• The Organon transaction must be financed without destroying capital efficiency.
• ROCE should remain attractive after future acquisitions.

What must Torrent Pharma prove?

• India base-business growth should remain above the market.
• JB Pharma's 35%-plus EBITDA margin needs to prove sustainable.
• Integration synergies must convert into consolidated cash flow.
• Net debt to EBITDA needs to decline.
• The US business should achieve sustainable profitability.
• Germany supply disruptions must be resolved.
• Earnings growth must justify a nearly 78x trailing P/E.

What could make Torrent outperform Sun Pharma?

Faster domestic branded growth plus acquisition deleveraging.

If Torrent sustains high-teens India growth, preserves a 33%-plus EBITDA margin and uses cash flow to reduce acquisition debt, PAT can grow much faster than the current Q1 number.

JB Pharma synergies amplify that possibility.

What could make Sun outperform Torrent?

Specialty growth without valuation expansion.

Sun already trades at roughly half Torrent's P/E.

If Innovative Medicines, India formulations and complex products compound steadily, shareholders do not need a dramatically higher multiple to generate returns.

Its stronger current balance sheet also gives it more strategic flexibility.

Which has the stronger current India franchise?

Sun Pharma on absolute scale.

India formulations generated approximately ₹5,475 crore in Q1 and Sun remains India's largest pharmaceutical company.

Torrent's base India business is smaller but grew faster at 19%.

Which has the stronger current margin?

Torrent Pharma.

Its operating EBITDA margin was 33.8% versus Sun Pharma's 28.9%.

Which has the stronger specialty-medicines exposure?

Sun Pharma.

Innovative Medicines already generate approximately 22% of sales.

Which has the stronger balance sheet today?

Sun Pharma.

Sun entered Q1 with substantial net cash, while Torrent's combined net debt to EBITDA was around 2.07x following the JB transaction.

Which has the stronger valuation?

Sun Pharma by a wide margin.

Its trailing P/E of roughly 38.8x is about half Torrent's 77.9x.

Which is better: Sun Pharma or Torrent Pharma?

Sun Pharma currently has the stronger risk-adjusted overall profile. It has more than three times Torrent's revenue, more than five times its Q1 PAT, greater global diversification, meaningful innovative-specialty exposure, higher current ROCE and a much lower earnings multiple.

Torrent Pharma currently has the stronger margin and domestic-growth profile. Its base India business grew 19%, consolidated operating EBITDA margin reached 33.8%, and JB Pharma is already generating a 35.3% operating margin.

The valuation gap is the deciding factor.

Torrent's operating quality is real, but a nearly 78x trailing P/E leaves much less room for integration or growth disappointment.

Sun's roughly 39x multiple is still premium, but the business offers broader earnings diversification and a lower starting hurdle.

At September 2026 valuations, Sun Pharma has the stronger valuation-adjusted franchise; Torrent remains the higher-margin, faster domestic-growth alternative for investors willing to pay substantially more for execution and JB Pharma synergy potential.

Frequently asked questions